What’s Propelling ZIOPHARM Oncology, Inc. (ZIOP) to Increase So Much?

December 7, 2017 - By Michael Collier

The stock of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) is a huge mover today! The stock increased 8.50% or $0.34 during the last trading session, reaching $4.34. About 2.10M shares traded or 37.48% up from the average. ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) has risen 1.75% since December 7, 2016 and is uptrending. It has underperformed by 14.95% the S&P500.
The move comes after 5 months positive chart setup for the $610.34M company. It was reported on Dec, 7 by Barchart.com. We have $4.51 PT which if reached, will make NASDAQ:ZIOP worth $24.41M more.

Analysts await ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to report earnings on February, 15. They expect $-0.13 earnings per share, down 18.18 % or $0.02 from last year’s $-0.11 per share. After $-0.13 actual earnings per share reported by ZIOPHARM Oncology, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Coverage

Among 4 analysts covering Ziopharm Oncology (NASDAQ:ZIOP), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Ziopharm Oncology had 6 analyst reports since December 4, 2015 according to SRatingsIntel. Mizuho maintained the shares of ZIOP in report on Wednesday, May 11 with “Neutral” rating. As per Wednesday, August 10, the company rating was upgraded by Wells Fargo. The rating was initiated by Wells Fargo with “Underperform” on Friday, December 4. Mizuho maintained ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) rating on Monday, January 25. Mizuho has “Neutral” rating and $6 target. Raymond James initiated the stock with “Market Perform” rating in Thursday, June 2 report.

More recent ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) news were published by: Globenewswire.com which released: “ZIOPHARM Oncology to Host Conference Call on November 20, 2017 at 10:15 am ET …” on November 17, 2017. Also Seekingalpha.com published the news titled: “ZIOPHARM tries to break downtrend, shares up 6%” on November 15, 2017. Fool.com‘s news article titled: “The case for Celldex Therapeutics, Inc.” with publication date: November 30, 2017 was also an interesting one.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company has market cap of $610.34 million. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to IntrexonÂ’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma . It currently has negative earnings. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.